Press Releases Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 08/12/2025 GMT			5-day change	1st Jan Change
997.59 ^USD	-1.26%		-5.70%	+29.22%

12-08	Health Care Down Amid Intensified Obesity-Drug Competition - Health Care Roundup	DJ
12-08	Eli Lilly declares Q1 2026 dividend of $1.73 per share	RE

Press Releases

Lilly declares first-quarter 2026 dividend	12-08	PR
GLP-1 Agonists Market: Driving Innovation and Growth in Metabolic and Cardiovascular Care	12-08	AQ
Carolyn Bertozzi returns to Lilly board of directors	12-08	PR
Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)	12-07	PR
Eli Lilly and : Lilly and IU to expand access to clinical trials and latest innovative treatments for Hoosiers	12-03	PU
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor	12-03	PR
Lilly lowers the price of Zepbound single-dose vials	12-02	AQ
BMO Launches New CDRs With Exposure to U.S. Stocks Including Microsoft, Eli Lilly, Exxon, Chevron and Robinhood	11-26	AQ
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium	11-24	PR
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting	11-24	PR
Lilly announces plans to open Lilly Gateway Labs site in Philadelphia	11-19	PR
Lilly to participate in Citi's 2025 Global Healthcare Conference	11-18	PR
Novo cuts Wegovy prices, but doctors still see cost challenges for patients	11-17	AQ
Statement: Eli Lilly has no affiliation with Mangoceuticals, Inc.	11-13	PU
Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth	11-06	PR
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans	11-06	PR
Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight	11-06	PR
Counting Patents, Not Progress: Another Misdiagnosis By I-MAK	11-05	AQ
Eli Lilly to build $3B pharmaceutical plant in the Netherlands	11-04	AQ
Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide	11-03	PR
Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war	10-30	AQ
Eli Lilly and : Q3 2025 Lilly Press Release	10-30	PU
Eli Lilly and : Q3 2025 Lilly Presentation	10-30	PU
Lilly: Q3 Earnings Snapshot	10-30	AQ
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance	10-30	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound

December 01, 2025 at 03:39 pm

Is it back to square one for Eli Lilly?

August 07, 2025 at 04:20 pm